Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-9901 in Relapsed/Refractory Lymphomas
NCT02258555Phase 1Terminated
- Sponsor
- Gilead Sciences
- Start
- Jan 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GS-9901 in follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukemia (CLL) and 1 more, sponsored by Gilead Sciences. Primary endpoint: Occurrence of adverse events (AEs) and clinical laboratory abnormalities defined as dose limiting toxicities (DLTs) up to 28 days. Started Jan 2015; status: terminated.
02
Drugs
GS-9901
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02258555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02258555.